Naidu A Satyanarayan, Wang Chin-Kun, Rao Pingfan, Mancini Fabrizio, Clemens Roger A, Wirakartakusumah Aman, Chiu Hui-Fang, Yen Chi-Hua, Porretta Sebastiano, Mathai Issac, Naidu Sreus A G
Global Nutrition Healthcare Council (GNHC) Mission-COVID, Yorba Linda, CA, USA.
N-terminus Research Laboratory, 232659 Via del Rio, Yorba Linda, CA, 92887, USA.
NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2.
SARS-CoV-2, the etiological agent of COVID-19, is devoid of any metabolic capacity; therefore, it is critical for the viral pathogen to hijack host cellular metabolic machinery for its replication and propagation. This single-stranded RNA virus with a 29.9 kb genome encodes 14 open reading frames (ORFs) and initiates a plethora of virus-host protein-protein interactions in the human body. These extensive viral protein interactions with host-specific cellular targets could trigger severe human metabolic reprogramming/dysregulation (HMRD), a rewiring of sugar-, amino acid-, lipid-, and nucleotide-metabolism(s), as well as altered or impaired bioenergetics, immune dysfunction, and redox imbalance in the body. In the infectious process, the viral pathogen hijacks two major human receptors, angiotensin-converting enzyme (ACE)-2 and/or neuropilin (NRP)-1, for initial adhesion to cell surface; then utilizes two major host proteases, TMPRSS2 and/or furin, to gain cellular entry; and finally employs an endosomal enzyme, cathepsin L (CTSL) for fusogenic release of its viral genome. The virus-induced HMRD results in 5 possible infectious outcomes: asymptomatic, mild, moderate, severe to fatal episodes; while the symptomatic acute COVID-19 condition could manifest into 3 clinical phases: (i) hypoxia and hypoxemia (Warburg effect), (ii) hyperferritinemia ('cytokine storm'), and (iii) thrombocytosis (coagulopathy). The mean incubation period for COVID-19 onset was estimated to be 5.1 days, and most cases develop symptoms after 14 days. The mean viral clearance times were 24, 30, and 39 days for acute, severe, and ICU-admitted COVID-19 patients, respectively. However, about 25-70% of virus-free COVID-19 survivors continue to sustain virus-induced HMRD and exhibit a wide range of symptoms that are persistent, exacerbated, or new 'onset' clinical incidents, collectively termed as post-acute sequelae of COVID-19 (PASC) or long COVID. PASC patients experience several debilitating clinical condition(s) with >200 different and overlapping symptoms that may last for weeks to months. Chronic PASC is a cumulative outcome of at least 10 different HMRD-related pathophysiological mechanisms involving both virus-derived virulence factors and a multitude of innate host responses. Based on HMRD and virus-free clinical impairments of different human organs/systems, PASC patients can be categorized into 4 different clusters or sub-phenotypes: sub-phenotype-1 (33.8%) with cardiac and renal manifestations; sub-phenotype-2 (32.8%) with respiratory, sleep and anxiety disorders; sub-phenotype-3 (23.4%) with skeleto-muscular and nervous disorders; and sub-phenotype-4 (10.1%) with digestive and pulmonary dysfunctions. This narrative review elucidates the effects of viral hijack on host cellular machinery during SARS-CoV-2 infection, ensuing detrimental effect(s) of virus-induced HMRD on human metabolism, consequential symptomatic clinical implications, and damage to multiple organ systems; as well as chronic pathophysiological sequelae in virus-free PASC patients. We have also provided a few evidence-based, human randomized controlled trial (RCT)-tested, precision nutrients to reset HMRD for health recovery of PASC patients.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是冠状病毒病(COVID-19)的病原体,自身没有任何代谢能力;因此,该病毒病原体劫持宿主细胞代谢机制以进行复制和传播至关重要。这种基因组为29.9 kb的单链RNA病毒编码14个开放阅读框(ORF),并在人体内引发大量病毒与宿主的蛋白质-蛋白质相互作用。这些广泛的病毒蛋白与宿主特异性细胞靶点的相互作用可能引发严重的人类代谢重编程/失调(HMRD),即糖代谢、氨基酸代谢、脂质代谢和核苷酸代谢的重新布线,以及体内生物能量学改变或受损、免疫功能障碍和氧化还原失衡。在感染过程中,病毒病原体劫持两种主要的人类受体,血管紧张素转换酶(ACE)-2和/或神经纤毛蛋白(NRP)-1,用于初始粘附于细胞表面;然后利用两种主要的宿主蛋白酶,跨膜丝氨酸蛋白酶2(TMPRSS2)和/或弗林蛋白酶,进入细胞;最后利用一种内体酶组织蛋白酶L(CTSL)实现病毒基因组的融合释放。病毒诱导的HMRD导致5种可能的感染结果:无症状、轻度、中度、重度至致命发作;而有症状的急性COVID-19病情可表现为3个临床阶段:(i)缺氧和低氧血症(瓦伯格效应),(ii)高铁蛋白血症(“细胞因子风暴”),以及(iii)血小板增多症(凝血病)。据估计,COVID-19发病的平均潜伏期为5.1天,大多数病例在14天后出现症状。急性、重度和入住重症监护病房(ICU)的COVID-19患者的平均病毒清除时间分别为24天、30天和39天。然而,约25%-70%的无病毒COVID-19幸存者继续承受病毒诱导的HMRD,并表现出一系列持续、加重或新“发作”的临床症状,统称为COVID-19急性后遗症(PASC)或长期COVID。PASC患者会经历几种使人衰弱的临床病症,有200多种不同且重叠的症状,可能持续数周甚至数月。慢性PASC是至少10种不同的与HMRD相关的病理生理机制的累积结果,涉及病毒衍生的毒力因子和多种先天性宿主反应。基于不同人体器官/系统的HMRD和无病毒临床损伤,PASC患者可分为4种不同的组群或亚表型:亚表型1(33.8%),有心脏和肾脏表现;亚表型2(32.8%),有呼吸、睡眠和焦虑障碍;亚表型3(23.4%),有骨骼肌肉和神经障碍;亚表型4(10.1%),有消化和肺功能障碍。这篇叙述性综述阐明了SARS-CoV-2感染期间病毒劫持对宿主细胞机制的影响,病毒诱导的HMRD对人类代谢的后续有害影响、相应的有症状临床意义以及对多个器官系统的损害;以及无病毒PASC患者的慢性病理生理后遗症。我们还提供了一些基于证据、经过人类随机对照试验(RCT)检验的精准营养素,以重置HMRD,促进PASC患者恢复健康。